Torrent Pharmaceuticals · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Supply disruption from third-party manufacturer continues with no resolution timeline visible. Europe regulatory interactions between EMA and FDA extending resolution. Alternate supplier identification will take 3-4 quarters minimum.
Change of control creates business practice adjustments and process integration challenges. Q4 could see muted performance in both India and international JB operations before returning to normal in Q1 FY27.
Semaglutide filing with ANVISA under priority review but 11-12 competitors in queue. Expected 45-50% price erosion on launch. Approval timing remains at regulator's discretion with no guaranteed launch in Q4.
CEO and CFO of JB have already resigned. While historical attrition rates maintained post-acquisition announcement, loss of institutional knowledge during transition poses execution risk.
